A polymorphism in the CYP17 gene increases the risk of breast cancer.
A polymorphism in the CYP17 gene increases the risk of breast cancer.
复制标题
DOI：
--
复制
发表时间：
1997-03
期刊：
影响因子：
11.2
通讯作者：
H. Feigelson;G. Coetzee;L. Kolonel;R. Ross;B. Henderson
中科院分区：
文献类型：
--
作者：
H. Feigelson;G. Coetzee;L. Kolonel;R. Ross;B. Henderson
我们进行了一项病例对照研究，以确定CYP17基因的多态是否与乳腺癌的风险有关。我们发现携带A2等位基因的女性患晚期乳腺癌的风险增加。区域或转移性疾病的优势比为2.5[95%可信区间(CI)，1.07-5.94]。在对照组中，A1/A1基因型与月经初潮年龄较晚有关。与A1/A2和A2/A2基因型相比，A1纯合子女性患乳腺癌的优势比为0.47(CI，0.22-0.98)，初潮年龄较晚，而A1/A2和A2/A2基因携带者患乳腺癌的优势比为0.80(CI，0.51-1.27)，与此相比，初潮年龄较晚的A1/A1女性患乳腺癌的风险降低很大。这些发现表明，CYP17基因可能是排卵开始和晚期乳腺癌风险的生物标记物。
We conducted a case-control study to determine whether a polymorphism in the CYP17 gene was associated with risk of breast cancer. We found an increased risk of advanced breast cancer in women carrying an A2 allele. The odds ratio was 2.5 [95% confidence interval (CI), 1.07-5.94] for regional or metastatic disease. Among controls, the A1/A1 genotype was associated with a later age at menarche. The reduced risk of breast cancer associated with a later age of menarche was largely limited to A1/A1 women: odds ratio, 0.47 (CI, 0.22-0.98) for breast cancer and later age at menarche among A1 homozygotes compared with 0.80 (CI, 0.51-1.27) for A1/A2 and A2/A2 genotypes. These findings suggest that the CYP17 genotype may be a biomarker for the onset of ovulation and advanced breast cancer risk.